|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
EP3849537B1
(en)
|
2018-09-10 |
2024-10-23 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP3849535A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EA202190749A1
(ru)
|
2018-09-10 |
2021-07-09 |
Мирати Терапьютикс, Инк. |
Способы комбинированной терапии
|
|
JP2022500385A
(ja)
|
2018-09-10 |
2022-01-04 |
ミラティ セラピューティクス， インコーポレイテッド |
組み合わせ療法
|
|
MX2021002804A
(es)
|
2018-12-05 |
2021-07-15 |
Mirati Therapeutics Inc |
Terapias de combinacion.
|
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
|
MX2022002465A
(es)
|
2019-08-29 |
2022-05-19 |
Mirati Therapeutics Inc |
Inhibidores de kras g12d.
|
|
WO2021061749A1
(en)
|
2019-09-24 |
2021-04-01 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
PH12022551513A1
(en)
|
2019-12-20 |
2023-04-24 |
Mirati Therapeutics Inc |
Sos1 inhibitors
|
|
US20250195521A1
(en)
|
2020-09-03 |
2025-06-19 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
EP4210833A4
(en)
|
2020-09-11 |
2024-09-11 |
Mirati Therapeutics, Inc. |
CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
|
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2022061251A1
(en)
*
|
2020-09-18 |
2022-03-24 |
Plexxikon Inc. |
Compounds and methods for kras modulation and indications therefor
|
|
JP2023544450A
(ja)
|
2020-09-23 |
2023-10-23 |
エラスカ・インコーポレイテッド |
三環式ピリドン及びピリミドン
|
|
JP2023553492A
(ja)
|
2020-12-15 |
2023-12-21 |
ミラティ セラピューティクス， インコーポレイテッド |
アザキナゾリン汎ＫＲａｓ阻害剤
|
|
EP4262803A4
(en)
|
2020-12-16 |
2025-03-12 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
CA3203080A1
(en)
*
|
2020-12-22 |
2022-06-30 |
Hongqi Tian |
Preparation and application method of heterocyclic compound as kras inhibitor
|
|
WO2022171191A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Jingrui Biopharma Co., Ltd. |
Compounds as anticancer agents
|
|
TWI810803B
(zh)
*
|
2021-03-15 |
2023-08-01 |
大陸商藥雅科技（上海）有限公司 |
突變蛋白抑制劑的製備及其應用
|
|
TWI814234B
(zh)
*
|
2021-03-15 |
2023-09-01 |
大陸商藥雅科技（上海）有限公司 |
突變蛋白抑制劑的製備及其應用
|
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
US20240300980A1
(en)
*
|
2021-05-22 |
2024-09-12 |
Shanghai Kechow Pharma, Inc. |
Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
IL312381A
(en)
|
2021-11-05 |
2024-06-01 |
Frontier Medicines Corp |
KRAS G12C inhibitors
|
|
US20250250286A1
(en)
*
|
2021-11-30 |
2025-08-07 |
Beta Pharma, Inc. |
Fused pyrimidine derivatives as kras oncoprotein inhibitors
|
|
CN119212994A
(zh)
|
2021-12-17 |
2024-12-27 |
建新公司 |
作为shp2抑制剂的吡唑并吡嗪化合物
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
EP4547666A1
(en)
*
|
2022-06-29 |
2025-05-07 |
Frontier Medicines Corporation |
Methods for treatment of cancer
|
|
WO2024081674A1
(en)
|
2022-10-11 |
2024-04-18 |
Aadi Bioscience, Inc. |
Combination therapies for the treatment of cancer
|
|
JP2026503866A
(ja)
*
|
2022-10-31 |
2026-02-02 |
ベータ・ファーマ・インコーポレイテッド |
Ｋｒａｓオンコプロテイン阻害剤としての１，５－ナフチリジン誘導体
|
|
CN120659773A
(zh)
|
2022-11-09 |
2025-09-16 |
锐新医药公司 |
化合物、复合物以及其制备方法和用途
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CR20250420A
(es)
|
2023-04-07 |
2025-11-20 |
Revolution Medicines Inc |
Inhibidores macrocíclicos de ras
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
CN116120315B
(zh)
*
|
2023-04-19 |
2023-06-09 |
山东绿叶制药有限公司 |
一种kras g12c抑制剂及其应用
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
TW202529768A
(zh)
|
2023-09-29 |
2025-08-01 |
大陸商德昇濟醫藥（無錫）有限公司 |
癌症治療的療法
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2025085580A1
(en)
*
|
2023-10-17 |
2025-04-24 |
Windermere Therapeutics, Inc. |
Kras(g12d) inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025193878A1
(en)
*
|
2024-03-12 |
2025-09-18 |
Cogent Biosciences, Inc. |
Kras inhibitors
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|